SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

DEFR14A - SeaStar Medical Holding Corp (0001831868) (Filer)

DEF 14A - SeaStar Medical Holding Corp (0001831868) (Filer)

PRE 14A - SeaStar Medical Holding Corp (0001831868) (Filer)

SCHEDULE 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)

424B5 - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

3 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

3 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device (SCD) in five clinical indications, subject to U.S. Food & Drug Administration (FDA) approvals, of $25 to $33 billion. The following chart summarizes ranges of the adult SCD total addressable market

DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates. Date/Time:Wednesday, December 11, 4:30 p.m. ET / 1:30 p.m. PT  Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start

Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and September 30, 2023. The restatement will impact the accounting treatment and classification of certain outstanding warrants and the prepaid forward purchase arrangement that was terminated in

Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI. "We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update. "Recent clinical and regulatory successes have significantly improved and strengthened our company's prospects," said Eric Schlorff, SeaStar Medical CEO. "We are addressing the remaining administrative steps outlined by the U.S. Food and Drug Administration (FDA) for approval of the Selective Cytopheretic Device Pediatric (SCD-P

DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a business update conference call today at 4:00 p.m. Eastern time (1:00 p.m. Pacific time). During the call, management will provide a clinical and regulatory update and review the Company's value proposition, including the commercial opportunity. A slide presentation to accompany management's prepared remarks will be available on the webcast and on the Events and Presentations page of the Investors

Management to hold a business update conference call on August 22 beginning at 4:00 p.m. Eastern time DENVER, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2023 and provides a business update. "With the recent activation of a second clinical site, we now have two medical centers open for enrolling patients in our pivotal trial evaluating the safety and efficacy of our patented, first-in-class, cell-directed Selective Cyt

DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2023 and provides a business update. "Enrollment of the first patient in our pivotal NEUTRALIZE-AKI trial and activation of additional clinical trial sites are expected in the coming weeks. This trial is evaluating the safety and efficacy of our patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with acut

DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022. "We are focusing on executing near-term milestones that will advance our business," said Eric Schlorff, SeaStar Medical CEO. "Our immediate efforts are aimed at raising awareness with the medical community of our cell-directed extracorporeal therapy's potential for playing a life-saving role for critically ill patients, working with regulators to

DENVER, Feb. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (NASDAQ:ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces it will hold a conference call to discuss business updates including the recent FDA approval to conduct a pivotal trial evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury (AKI) and an update regarding the Humanitarian Device Exemption (HDE) submission for market approval for use of the SCD for critically ill children with AKI. Date/Time:Wednesday, February 15, 4:00 p.m. ET / 1:00 p.m. PT  Pre-Regis

DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rule, with a single institutional investor for the issuance and sale of an aggregate of 3,529,412 shares of its common stock (or pre-funded warrants in lieu thereof). In a concurrent private placement, the Company issued and sold to the investor warrants to purchase up to an aggregate of 3,529,412 shares common stock. The combined offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants was $1.70 (or $1.699 with

DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of an aggregate of 3,529,412 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to an aggregate of 3,529,412 shares common stock. The combined offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants is $1.70 (or $1.699 with respect to

DENVER, Jan. 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage therapeutic medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has shipped QUELIMMUNE™ to a California medical center recognized as a world leader in pediatric research and treatments, increasing commercial customers to five. QUELIMMUNE is the company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis. "We are delighted that QUELIMMUNE is now available to treat severely ill children at yet another prominent academ

DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Mayo Clinic is now cleared to enroll subjects in the company's NEUTRALIZE-AKI pivotal trial, increasing the number of activated sites to 15. "We are thrilled to activate another large academic center to our study," said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. "Enrollment in the trial currently stands at 76 with six subjects enrolled since the first of the year. We look forward to our next major milestone of reaching our 100th s

Study to be conducted under $3.6 million NIH grant  DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar Medical's Selective Cytopheretic Device (SCD-ADULT) in reducing inflammation in adult patients with acute heart failure with worsening renal function due to cardiorenal syndrome or severe right ventricular failure awaiting a left ve

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the shipment of its QUELIMMUNE™ device to a prominent academic medical center, representing SeaStar Medical's fourth commercial customer. QUELIMMUNE is the company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis. "We are pleased to expand commercial access to QUELIMMUNE and are extremely proud to be the only company to develop and commercialize a ther

DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that a 14th site is now activated and able to enroll subjects in the NEUTRALIZE-AKI pivotal trial. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company's proprietary therapeutic Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous renal replacement therapy (CRRT). "We are pleased to welcome the 14th hospital to our trial, especially as this site ha

U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device (SCD) in five clinical indications, subject to U.S. Food & Drug Administration (FDA) approvals, of $25 to $33 billion. The following chart summarizes ranges of the adult SCD total addressable market

DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates. Date/Time:Wednesday, December 11, 4:30 p.m. ET / 1:30 p.m. PT  Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start

DENVER, Dec. 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the activation of Sentara Norfolk General Hospital in Norfolk, Virginia as its thirteenth active site in its NEUTRALIZE-AKI pivotal trial. The Company also reports the enrollment of nine critically ill adult acute kidney injury (AKI) patients in the trial during November, bringing total trial enrollment to 65 subjects. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company's proprietary therapeutic Selective Cytopheretic Device (